Please use this identifier to cite or link to this item:
Title: Hospital costs of nosocomial multi-drug resistant pseudomonas aeruginosa acquisition
Author: Morales, Eva
Cots Reguant, Francesc
Sala, María Luisa
Comas Serrano, Mercè
Belvis, Francesc
Riu, Marta
Salvadó, Margarita
Grau, Santiago
Horcajada, Juan P.
Milagro Montero, Maria
Castells Oliveres, Xavier
Others: Universitat Oberta de Catalunya (UOC)
Keywords: antimicrobial resistance
economic analysis
hospital cost
multi-drug resistance
pseudomonas aeruginosa
Issue Date: 23-May-2012
Publisher: BMC Health Services Research
Citation: Morales, E., Cots Reguant, F., Sala, M.L., Comas, M., Belvis, F., Riu, M., Salvado, M., Grau, S., Horcajada, J.P. & Milagro Montero, M.(2012). Hospital costs of nosocomial multi-drug resistant pseudomonas aeruginosa acquisition. BMC Health Services Research, 12(1). doi: 10.1186/1472-6963-12-122
Also see:
Abstract: We aimed to assess the hospital economic costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive clinical culture for P. aeruginosa more than 48 h after admission were included. Patient and hospitalization characteristics were collected from hospital and microbiology laboratory computerized records. According to antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods. Multivariate analyses were performed using generalized linear models of log-transformed costs.
Language: English
ISSN: 1472-6963MIAR
Appears in Collections:Articles

Files in This Item:
File Description SizeFormat 
costs.pdf275.33 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons